Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
43.38 USD | -0.99% | -4.35% | +17.86% |
May. 22 | Halozyme Therapeutics Insider Sold Shares Worth $905,480, According to a Recent SEC Filing | MT |
May. 07 | Halozyme Therapeutics Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.86% | 5.58B | |
+10.75% | 118B | |
+10.56% | 106B | |
-11.46% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.47% | 15.97B | |
+7.08% | 14.03B | |
+16.26% | 11.67B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Transcript : Halozyme Therapeutics, Inc. Presents at Bank of America Securities 2023 Healthcare Conference, May-10-2023 04